News – Akiram Therapeutics https://akiramtherapeutics.se Advancing radiotherapeutics to treat solid tumors Thu, 30 Apr 2026 13:42:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.2 https://akiramtherapeutics.se/wp-content/uploads/2022/08/cropped-Targeted-tumor-cell-32x32.png News – Akiram Therapeutics https://akiramtherapeutics.se 32 32 Marika Nestor featured in SSF’s Om Vetenskap podcast https://akiramtherapeutics.se/marika-nestor-featured-in-ssfs-om-vetenskap-podcast/ Thu, 30 Apr 2026 13:42:53 +0000 https://akiramtherapeutics.se/?p=943 How can drugs be designed to target diseased cells with high precision? In a recent episode of Om Vetenskap, the podcast by the Swedish Foundation for Strategic Research (SSF), Akiram Therapeutics’ CEO and co-founder, Professor Marika Nestor, discusses the development of targeted radiopharmaceutical therapies and their potential to transform cancer treatment.

The episode explores the concept of targeted therapies designed to seek out and act directly on diseased cells rather than affecting the entire body. The conversation highlights recent advances in the field, how it is being developed, and what it could mean for the future of healthcare.

Marika Nestor participates alongside Peter Nilsson, Professor of Organic Chemistry at Linköping University, in a discussion led by SSF’s Sofie Pehrsson.

Listen to the episode (in Swedish):
https://strategiska.se/malsokande-lakemedelsmolekyler/

]]> A pioneer in targeted radiotherapy – Marika Nestor featured in Onkologi i Sverige https://akiramtherapeutics.se/a-pioneer-in-targeted-radiotherapy-marika-nestor-featured-in-onkologi-i-sverige/ Mon, 10 Nov 2025 12:18:59 +0000 https://akiramtherapeutics.se/?p=890 What drives a cancer researcher to start a biotech company? In a newly published feature in Onkologi i Sverige, our CEO and co-founder, Professor Marika Nestor, shares insights from her journey through academia, innovation, and translational cancer research.

Marika Nestor

The article traces her early steps into science, the growth of her all-female research group in Uppsala, and her longstanding focus on developing targeted radiopharmaceutical therapies for difficult-to-treat cancers. It also touches on the founding of Akiram Therapeutics as a way to bring research closer to clinical application and patient benefit.

Read the full article (in Swedish) on Onkologi i Sverige:
Nestorn i strålterapi: på en strålande väg mot nya cancerläkemedel

]]> Leading the future of radioimmunotherapy for cancer treatment https://akiramtherapeutics.se/leading-the-future-of-radioimmunotherapy-for-cancer-treatment/ Mon, 09 Dec 2024 08:53:49 +0000 https://akiramtherapeutics.se/?p=792

Our CEO, Professor Marika Nestor discusses advancing cancer treatment through radioimmunotherapy in a new interview ahead of her presentation at Antibody Engineering & Therapeutics. The interview highlights Akiram’s recent milestone: the approval of a Phase 1 clinical trial for 177Lu-AKIR001, a novel radiolabeled antibody targeting cancers with high CD44v6 expression, including head and neck squamous cell carcinoma.

The discussion explores how targeted radioimmunotherapy addresses both primary tumours and metastatic lesions, marking a significant innovation in next-generation cancer therapies—a key focus of Akiram’s development programme.

Read the full interview from Antibody Engineering & Therapeutics here.

]]> DDD exit financed with 68 MSEK to develop novel cancer therapy https://akiramtherapeutics.se/ddd-exit-financed-with-68-msek-to-develop-novel-cancer-therapy/ Wed, 08 Feb 2023 11:00:53 +0000 https://akiramtherapeutics.se/?p=619 In June 2022, Marika Nestor’s project aiming to develop a novel cancer therapy left the DDD Platform at SciLifeLab. Six months later, the resulting spin-out company Akiram Therapeutics raised 68 MSEK and is heading for clinical trials in 2024.

Read the full SciLifeLab news item here.

]]> She is creating brilliant chances for cancer patients https://akiramtherapeutics.se/she-is-creating-brilliant-chances-for-cancer-patients/ Mon, 04 Jul 2022 11:00:00 +0000 https://akiramtherapeutics.se/?p=653 Radiopharmaceuticals that fight cancer are on the rise and Marika Nestor is doing everything she can to contribute to their development. An antibody from her lab offers hope for a future treatment for those affected by anaplastic thyroid cancer, a currently incurable form of cancer.

Read the full news item from Uppsala University here (in Swedish).

]]> Latest DDD-exit: Radioactive antibody for treatment of aggressive cancer https://akiramtherapeutics.se/latest-ddd-exit-radioactive-antibody-for-treatment-of-aggressive-cancer/ Wed, 08 Jun 2022 11:00:00 +0000 https://akiramtherapeutics.se/?p=650 A new antibody might be the first effective treatment for Anaplastic thyroid cancer (ATC), a very aggressive cancer type with a median survival of only 4-5 month even with available treatments. The radiolabeled antibody is the result of a four-year long successful collaboration between SciLifeLab researcher Marika Nestor (Uppsala University) and the SciLifeLab Drug Discovery and Development (DDD) platform.

Read the full SciLifeLab news item here.

]]>